Ablynx NV, of Ghent, Belgium, disclosed positive results from the phase I trial to demonstrate bioequivalence between the liquid and lyophilized formulations of caplacizumab, Ablynx's anti-von Willebrand factor nanobody developed for the treatment of acquired thrombotic thrombocytopenic purpura.